Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05534347

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rheumatology Department, Cochin Hospital

Paris, IDF, 75014, France

Location status: Recruiting

Location contact

Yannick ALLANORE, MD, PhD

CONTACT

[email protected]

0033158412572

About this study

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.

The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Greater than or equal to 16 years-old
  • Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
  • No-opposition to the research
  • Patient with health insurance
  • Mastery of the French language

Exclusion criteria

  • Patient under curatorship or guardianship
  • Patient receiving french state medical aid

Treatment and study plan

Blood sample

Biological

Addtional tube of blood needed for follow up of patients

Joint puncture

Biological

Joint puncture if needed according to routine care of the patients

Primary outcomes

  1. Dosage of angiogenic markers

    Time frame: 5 years

    Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

    Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  2. Dosage of angiogenic markers

    Time frame: 5 years

    Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

    Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  3. Dosage of inflammatory markers by ELISA method

    Time frame: 5 years

    Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

    Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  4. Dosage of inflammatory markers by ELISA method

    Time frame: 5 years

    Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received.

    Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Secondary outcomes

  1. Questionnaires

    Time frame: 5 years

    Severity of JIA

  2. Collection of treatments received

    Time frame: 5 years

    Severity of JIA

  3. Structural damage determined by x-rays

    Time frame: 5 years

    Structural damage determined by x-rays during follow up.

  4. Angiogenic biomarkers

    Time frame: At inclusion

    Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.

  5. Inflammatory biomarkers

    Time frame: At inclusion

    Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA.

Study contacts

Contact information is provided by the study sponsor or research team.

Marie BENHAMMANI-GODARD

CONTACT

[email protected]

+33 1 58411190

Yannick ALLANORE, PD, PhD

CONTACT

[email protected]

0033158412563

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis

Acronym: MAJIC

Important dates

Study start
2023
Primary completion
2030
Study completion
2030
First posted
Sep 9, 2022
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.